Upload folder using huggingface_hub

README.md

@@ -0,0 +1,115 @@
+---
+language:
+- en
+task_categories:
+- question-answering
+- information-retrieval
+tags:
+- multi-hop-qa
+- causal-reasoning
+- knowledge-graph
+- long-form-qa
+- beir
+- biomedical
+- rare-disease
+- gaucher-disease
+license: mit
+size_categories:
+- n<1K
+---
+
+# Gaucher Disease QA
+
+A long-form, multi-hop question answering dataset about Gaucher disease, a rare lysosomal storage disorder caused by mutations in the GBA1 gene.
+
+## Dataset Description
+
+This dataset contains 25 expert-curated causal reasoning questions grounded in 20 biomedical articles covering the genetics, pathophysiology, clinical manifestations, and treatment of Gaucher disease. Each question requires synthesizing information from multiple source documents to produce a comprehensive answer, making it a challenging benchmark for multi-hop QA and biomedical causal inference.
+
+### Key Properties
+
+- **Domain**: Biomedical / rare disease / genetics
+- **Question type**: Long-form causal reasoning (not extractive)
+- **Multi-hop**: Every question requires evidence from 2-4 source documents
+- **Total queries**: 25
+- **Total documents**: 20
+- **Total relevance judgments**: 86
+- **Average documents per query**: 3.4
+
+## Dataset Format (BEIR-style)
+
+The dataset follows the [BEIR](https://github.com/beir-cellar/beir) format with three JSONL files:
+
+### `queries.jsonl`
+```json
+{"id": "q1", "question": "How does a mutation in the GBA gene disrupt the catalytic activity of glucocerebrosidase?", "answer": "Mutations in the GBA gene can cause the enzyme to fold improperly..."}
+```
+
+### `corpus.jsonl`
+```json
+{"id": "doc1", "text": "Full article text..."}
+```
+
+### `qrels.jsonl`
+```json
+{"query_id": "q1", "doc_ids": ["doc1", "doc8", "doc15", "doc19"]}
+```
+
+## Topics Covered
+
+The questions span the full causal chain of Gaucher disease:
+
+- **Molecular basis**: GBA1 mutations, enzyme misfolding, residual activity, genotype-phenotype correlations
+- **Cellular pathology**: Glucocerebroside accumulation, Gaucher cell formation, lysosomal dysfunction
+- **Organ involvement**: Splenomegaly, hepatomegaly, bone marrow infiltration, impaired hematopoiesis
+- **Neurological complications**: Neuronopathic types 2/3, cognitive difficulties, Parkinson's disease link (alpha-synuclein/GCase vicious cycle)
+- **Metabolic effects**: Hypermetabolism (REE 44% elevated), GM3-mediated insulin resistance, AKT pathway disruption
+- **Clinical management**: ERT vs SRT (eliglustat/CYP2D6), splenectomy risks, biomarkers (chitotriosidase), imaging
+- **Emerging therapies**: Gene therapy (AAV vectors, BBB crossing)
+- **Genetics**: Autosomal recessive inheritance, genetic counseling
+
+## Usage
+
+```python
+from datasets import load_dataset
+
+dataset = load_dataset("jashparekh/gaucher-disease-qa")
+```
+
+Or load the JSONL files directly:
+
+```python
+import json
+
+queries = [json.loads(line) for line in open("queries.jsonl")]
+corpus = [json.loads(line) for line in open("corpus.jsonl")]
+qrels = [json.loads(line) for line in open("qrels.jsonl")]
+```
+
+## Intended Use
+
+- Benchmarking multi-hop question answering systems on biomedical text
+- Evaluating causal reasoning over scientific/medical document collections
+- Testing retrieval-augmented generation (RAG) pipelines on domain-specific content
+- Evaluating knowledge graph-based QA systems for rare disease information
+
+## Source
+
+All questions and gold answers were expert-curated and verified against the 20 source articles. The articles include clinical reviews, gene therapy research papers, patient-facing medical resources, and comprehensive disease overviews from sources such as GeneReviews, NORD, NIH, Mayo Clinic, and peer-reviewed journals.
+
+## Citation
+
+This dataset was created as part of the SARG (Structure-Augmented Reasoning Generation) project. If you use this dataset, please cite:
+
+```bibtex
+@article{parekh2025structure,
+  title={Structure-Augmented Reasoning Generation},
+  author={Parekh, Jash Rajesh and Jiang, Pengcheng and Han, Jiawei},
+  journal={arXiv preprint arXiv:2506.08364},
+  year={2025}
+}
+```
+
+## License
+
+MIT

qrels.jsonl

@@ -0,0 +1,25 @@
+{"query_id": "q1", "doc_ids": ["doc1", "doc8", "doc15", "doc19"]}
+{"query_id": "q2", "doc_ids": ["doc6", "doc9", "doc12", "doc19"]}
+{"query_id": "q3", "doc_ids": ["doc6", "doc8", "doc19"]}
+{"query_id": "q4", "doc_ids": ["doc1", "doc6", "doc9", "doc11"]}
+{"query_id": "q5", "doc_ids": ["doc5", "doc6", "doc10", "doc19"]}
+{"query_id": "q6", "doc_ids": ["doc6", "doc9", "doc19", "doc20"]}
+{"query_id": "q7", "doc_ids": ["doc1", "doc9", "doc12", "doc19"]}
+{"query_id": "q8", "doc_ids": ["doc9", "doc10"]}
+{"query_id": "q9", "doc_ids": ["doc1", "doc8", "doc9", "doc15"]}
+{"query_id": "q10", "doc_ids": ["doc1", "doc6", "doc9", "doc19"]}
+{"query_id": "q11", "doc_ids": ["doc2", "doc9", "doc11"]}
+{"query_id": "q12", "doc_ids": ["doc1", "doc6", "doc13", "doc14"]}
+{"query_id": "q13", "doc_ids": ["doc4", "doc6", "doc9", "doc19"]}
+{"query_id": "q14", "doc_ids": ["doc3", "doc4", "doc10"]}
+{"query_id": "q15", "doc_ids": ["doc10", "doc13", "doc16"]}
+{"query_id": "q16", "doc_ids": ["doc6", "doc9", "doc11", "doc19"]}
+{"query_id": "q17", "doc_ids": ["doc9", "doc10", "doc19"]}
+{"query_id": "q18", "doc_ids": ["doc5", "doc6", "doc10", "doc19"]}
+{"query_id": "q19", "doc_ids": ["doc1", "doc9", "doc19"]}
+{"query_id": "q20", "doc_ids": ["doc3", "doc4", "doc11", "doc16"]}
+{"query_id": "q21", "doc_ids": ["doc9", "doc16", "doc18"]}
+{"query_id": "q22", "doc_ids": ["doc6", "doc9", "doc10", "doc19"]}
+{"query_id": "q23", "doc_ids": ["doc9", "doc10"]}
+{"query_id": "q24", "doc_ids": ["doc9", "doc13", "doc19"]}
+{"query_id": "q25", "doc_ids": ["doc1", "doc8"]}

queries.jsonl

@@ -0,0 +1,25 @@
+{"id": "q1", "question": "How does a mutation in the GBA gene disrupt the catalytic activity of glucocerebrosidase?", "answer": "Mutations in the GBA gene can cause the enzyme to fold improperly, reducing its stability and catalytic activity. This leads to insufficient hydrolysis of glucocerebroside, causing the substrate to accumulate in lysosomes."}
+{"id": "q2", "question": "Why does glucocerebroside primarily accumulate in macrophages in Gaucher disease?", "answer": "Macrophages are the body's primary scavengers of cellular debris and lipids, making them more susceptible to lipid overload when enzyme activity is impaired."}
+{"id": "q3", "question": "Why does reduced glucocerebrosidase activity in Gaucher disease increase the risk of developing Parkinson's disease?", "answer": "Reduced glucocerebrosidase (GCase) activity compromises lysosomal degradation of alpha-synuclein, causing it to accumulate. The glucosylceramide substrate directly stabilizes soluble alpha-synuclein oligomers, which aggregate to form Lewy bodies in nerve cells of the substantia nigra. These alpha-synuclein oligomers in turn inhibit GCase activity, creating a self-reinforcing vicious cycle that leads to neurotoxicity. Patients with Gaucher disease type 1 have a 4 to 20 times greater risk of developing Parkinson's disease, often at an earlier age, and heterozygous GBA carriers carry approximately a five-fold risk."}
+{"id": "q4", "question": "How does enzyme replacement therapy (ERT) improve clinical symptoms in Gaucher disease by addressing the underlying enzyme deficiency?", "answer": "ERT supplies a functional glucocerebrosidase enzyme, reducing glucocerebroside accumulation in peripheral tissues and alleviating clinical symptoms despite limited CNS penetration."}
+{"id": "q5", "question": "How do specific point mutations in the GBA gene influence residual glucocerebrosidase activity and determine the clinical severity of Gaucher disease?", "answer": "Different point mutations lead to varying degrees of glucocerebrosidase deficiency, affecting the breakdown of glucocerebroside and resulting in a spectrum of clinical severities."}
+{"id": "q6", "question": "How does the accumulation of undigested glucocerebroside lead to splenomegaly and hepatomegaly in Gaucher disease?", "answer": "Glucocerebrosidase deficiency causes glucocerebroside buildup in macrophages, which infiltrate and enlarge the spleen and liver."}
+{"id": "q7", "question": "How are Gaucher cells formed as a consequence of glucocerebrosidase deficiency?", "answer": "Insufficient enzyme activity causes macrophages to accumulate lipids, transforming them into Gaucher cells that are characteristic of the disease."}
+{"id": "q8", "question": "Why is there variability in bone pain and fracture risk among patients with Gaucher disease?", "answer": "Glucocerebroside in cells can cause inflammation and interfere with lipid metabolism and bone remodeling, resulting in variability in bone pain and fracture risk."}
+{"id": "q9", "question": "How does the deficiency of glucocerebrosidase impair lysosomal function in Gaucher disease?", "answer": "The lack of the glucocerebrosidase enzyme leads to glucocerebroside buildup within lysosomes, disrupting their function and leading to Gaucher disease symptoms."}
+{"id": "q10", "question": "How does substrate reduction therapy treat Gaucher disease differently from enzyme replacement therapy?", "answer": "While enzyme replacement therapy restores deficient glucocerebrosidase levels by intravenous infusion of recombinant enzyme, substrate reduction therapy takes the opposite approach by using oral glucosylceramide synthase inhibitors to reduce the rate of substrate synthesis. Eliglustat tartrate, the most commonly used SRT, is more specific and potent than the earlier miglustat because it is an analogue of the ceramide portion of glucosylceramide. However, eliglustat dosing depends on the patient's CYP2D6 metabolism and is not indicated for ultra-rapid metabolizers or patients with hepatic impairment. Currently, children are excluded from SRT therapeutic indications."}
+{"id": "q11", "question": "How does a mutation in the GBA gene lead to anemia and fatigue in Gaucher disease, ultimately impairing daily activities?", "answer": "Mutations in the GBA gene reduce enzyme activity, leading to lipid accumulation that disrupts blood cell production and results in anemia and fatigue."}
+{"id": "q12", "question": "How do mutations in the GBA1 gene contribute to cognitive difficulties in Gaucher disease patients?", "answer": "Cognitive difficulties occur in neuronopathic forms of Gaucher disease (types 2 and 3), where glucocerebroside accumulates in the brain due to deficient glucocerebrosidase activity. Because recombinant enzyme cannot cross the blood-brain barrier, ERT is ineffective against neurological manifestations. Neuropathological studies show neuronal loss, microgliosis, and astrogliosis. Type 2 (acute neuronopathic) presents in infancy with rapid neurological decline, while type 3 (chronic neuronopathic) causes progressive cognitive difficulties, abnormal horizontal saccadic eye movements, seizures, myoclonus, and ataxia."}
+{"id": "q13", "question": "How does cellular damage resulting from GBA1 gene mutations increase the risk of malignancy in Gaucher disease?", "answer": "Severe reduction in enzyme activity due to GBA1 mutations leads to toxic lipid buildup and tissue damage, creating a pro-inflammatory environment that promotes malignancies."}
+{"id": "q14", "question": "How does early detection of Gaucher disease influence growth and development outcomes in affected children?", "answer": "Early diagnosis allows timely intervention that can mitigate delayed growth and puberty, reducing the risk of growth retardation in children with Gaucher disease."}
+{"id": "q15", "question": "Why is splenectomy now generally avoided in Gaucher disease patients, and what complications does it cause?", "answer": "Although splenectomy normalizes platelet counts by eliminating hypersplenism, it is now generally avoided because it accelerates disease burden in other organs. Splenectomised patients have a five-fold higher prevalence of gallstones and are more often overweight or obese compared with non-splenectomised patients. Bone disease may continue to progress despite splenectomy. The advent of enzyme replacement therapy provides a safer alternative that reduces spleen volume without removing the organ, and rapid implementation of ERT with avoidance of splenectomy may reduce the risk of these long-term complications."}
+{"id": "q16", "question": "How does the replacement of bone marrow by Gaucher cells lead to impaired hematopoiesis in Gaucher disease?", "answer": "Infiltration of Gaucher cells into the bone marrow disrupts normal blood cell production, resulting in anemia, fatigue, and compromised hematopoiesis."}
+{"id": "q17", "question": "How do mutations in the GBA1 gene lead to cellular damage that may intersect with other metabolic disorders?", "answer": "GBA1 mutations drastically reduce lysosomal enzyme activity, causing toxic lipid buildup and cellular damage that can contribute to broader metabolic dysregulation."}
+{"id": "q18", "question": "How do variations in residual glucocerebrosidase activity influence treatment responses among Gaucher disease patients?", "answer": "Differences in residual enzyme activity due to varying mutations affect lipid accumulation, leading to variable responses to therapies such as ERT and SRT."}
+{"id": "q19", "question": "How does the imbalance between the formation and breakdown of glucocerebroside lead to the development of Gaucher cells and altered cellular signaling?", "answer": "An imbalance in enzyme activity results in lipid accumulation in lysosomes, which triggers Gaucher cell formation and disrupts cellular signaling."}
+{"id": "q20", "question": "How does understanding the inheritance pattern of Gaucher disease help families manage the risk of severe clinical outcomes?", "answer": "Genetic counseling based on the autosomal recessive inheritance of Gaucher disease enables families to assess risks and plan proactive measures."}
+{"id": "q21", "question": "How can advanced imaging techniques be used to monitor Gaucher disease progression?", "answer": "MRI and CT scans can detect organ enlargement and bone lesions, providing objective measures to track disease progression over time."}
+{"id": "q22", "question": "How does the accumulation of lipid substrates in Gaucher cells serve as a biomarker for disease severity?", "answer": "Elevated lipid buildup in Gaucher cells as reflected by biomarkers like chitotriosidase correlates with the extent of enzyme deficiency and overall disease severity."}
+{"id": "q23", "question": "How does Gaucher disease affect resting energy expenditure and insulin sensitivity, and how does enzyme replacement therapy alter these metabolic parameters?", "answer": "Gaucher disease type 1 patients have resting energy expenditure approximately 44% higher than predicted, and basal hepatic glucose production is elevated by about 30%. Insulin resistance develops through accumulation of the glycosphingolipid GM3, which displaces insulin receptors from lipid rafts and disrupts the Protein Kinase B (AKT) pathway that controls glucose uptake, glycogen synthesis, and hepatic glucose production. Activated macrophages also secrete pro-inflammatory cytokines IL-6 and TNF-alpha, further contributing to insulin resistance. Paradoxically, ERT can worsen insulin sensitivity despite reducing substrate burden, because the reduction in resting energy expenditure leads to weight gain when caloric intake is not adjusted, and transient increases in ceramide levels during treatment may independently promote insulin resistance."}
+{"id": "q24", "question": "How does hypersplenism contribute to the increased risk of bleeding in patients with Gaucher disease?", "answer": "Enlarged spleens sequester platelets and other blood cells, leading to thrombocytopenia and impaired clotting, which increases bleeding risk."}
+{"id": "q25", "question": "How can gene therapy targeting GBA1 gene variants restore lysosomal function and reduce tissue damage in Gaucher disease?", "answer": "Gene therapy can introduce functional copies of the GBA1 gene, restoring enzyme activity, reducing toxic lipid buildup, and mitigating tissue damage."}